B-intervention	0	11	Palbociclib
O	12	14	as
O	15	21	single
O	22	27	agent
O	28	30	or
O	31	33	in
O	34	45	combination
O	46	50	with
O	51	54	the
O	55	64	endocrine
O	65	72	therapy
O	73	81	received
O	82	88	before
O	89	96	disease
O	97	108	progression
O	109	112	for
O	113	121	estrogen
O	122	130	receptor
O	130	131	-
O	131	139	positive
O	139	140	,
O	141	145	HER2
O	145	146	-
O	146	154	negative
O	155	165	metastatic
O	166	172	breast
O	173	179	cancer
O	179	180	:
O	181	186	TREnd
O	187	192	trial
O	192	193	.

O	194	197	The
O	198	206	activity
O	207	209	of
O	210	221	palbociclib
O	222	224	as
O	225	226	a
O	227	233	single
O	234	239	agent
O	240	242	in
O	243	251	advanced
O	252	258	breast
O	259	265	cancer
O	266	269	has
O	270	273	not
O	274	278	been
O	279	290	extensively
O	291	298	studied
O	298	299	,
O	300	304	with
O	305	308	the
O	309	313	only
O	314	323	available
O	324	332	clinical
O	333	337	data
O	338	345	limited
O	346	348	to
O	349	356	heavily
O	357	367	pretreated
O	368	376	patients
O	376	377	.

O	378	389	Preclinical
O	390	394	data
O	395	403	suggests
O	404	415	palbociclib
O	416	419	may
O	420	429	partially
O	430	437	reverse
O	438	447	endocrine
O	448	458	resistance
O	458	459	,
O	460	466	though
O	467	471	this
O	472	482	hypothesis
O	483	486	has
O	487	490	not
O	491	495	been
O	496	505	evaluated
O	506	508	in
O	509	517	previous
O	518	526	clinical
O	527	534	studies
O	534	535	.

O	536	540	This
O	541	546	phase
O	547	549	II
O	549	550	,
O	551	555	open
O	555	556	-
O	556	561	label
O	561	562	,
O	563	574	multicenter
O	575	580	study
O	581	589	examined
O	590	593	the
O	594	602	activity
O	603	605	of
O	606	617	palbociclib
O	618	629	monotherapy
O	629	630	,
O	631	633	as
O	634	638	well
O	639	641	as
O	642	653	palbociclib
O	654	659	given
O	660	662	in
O	663	674	combination
O	675	679	with
O	680	683	the
O	684	688	same
O	689	698	endocrine
O	699	706	therapy
O	707	708	(
O	708	710	ET
O	710	711	)
O	712	716	that
O	717	720	was
O	721	729	received
O	730	735	prior
O	736	738	to
O	739	746	disease
O	747	758	progression
O	758	759	,
O	760	762	in
O	763	777	postmenopausal
O	778	783	women
O	784	788	with
O	789	799	moderately
O	800	810	pretreated
O	810	811	,
O	812	820	estrogen
O	821	829	receptor
O	829	830	-
O	830	838	positive
O	838	839	,
O	840	844	HER2
O	845	853	negative
O	854	862	advanced
O	863	869	breast
O	870	876	cancer
O	876	877	.

O	878	886	Eligible
B-eligibility	887	892	women
I-eligibility	893	897	with
I-eligibility	898	906	advanced
I-eligibility	907	914	disease
I-eligibility	915	920	which
I-eligibility	921	924	had
I-eligibility	925	935	progressed
I-eligibility	936	938	on
I-eligibility	939	942	one
I-eligibility	943	945	or
I-eligibility	946	949	two
I-eligibility	950	955	prior
I-eligibility	956	959	ETs
O	960	964	were
O	965	975	randomized
O	976	977	1
O	978	979	:
O	980	981	1
O	982	984	to
O	985	992	receive
O	993	999	either
B-control	1000	1011	palbociclib
I-control	1012	1017	alone
O	1017	1018	,
O	1019	1021	or
O	1022	1033	palbociclib
O	1034	1036	in
O	1037	1048	combination
O	1049	1053	with
O	1054	1057	the
O	1058	1060	ET
O	1061	1063	as
O	1064	1074	previously
O	1075	1083	received
O	1083	1084	.

O	1085	1092	Primary
O	1093	1096	end
O	1097	1102	point
O	1103	1106	was
B-outcome-Measure	1107	1115	clinical
I-outcome-Measure	1116	1123	benefit
I-outcome-Measure	1124	1128	rate
I-outcome-Measure	1129	1130	(
I-outcome-Measure	1130	1133	CBR
I-outcome-Measure	1133	1134	)
O	1134	1135	;
O	1136	1145	secondary
O	1146	1149	end
O	1150	1156	points
O	1157	1165	included
B-outcome-Measure	1166	1177	progression
I-outcome-Measure	1177	1178	-
I-outcome-Measure	1178	1182	free
I-outcome-Measure	1183	1191	survival
I-outcome-Measure	1192	1193	(
I-outcome-Measure	1193	1196	PFS
I-outcome-Measure	1196	1197	)
O	1197	1198	.

O	1199	1206	Between
O	1207	1214	October
O	1215	1219	2012
O	1220	1223	and
O	1224	1228	July
O	1229	1233	2016
O	1233	1234	,
O	1235	1236	a
O	1237	1242	total
O	1243	1245	of
B-total-participants	1246	1249	115
O	1250	1258	patients
O	1259	1263	were
O	1264	1274	randomized
O	1274	1275	.

O	1276	1279	The
B-outcome	1280	1283	CBR
O	1284	1287	was
B-cv-bin-percent	1288	1290	54
I-cv-bin-percent	1290	1291	%
O	1292	1293	[
O	1293	1295	95
O	1295	1296	%
O	1297	1307	confidence
O	1308	1316	interval
O	1317	1318	(
O	1318	1320	CI
O	1320	1321	)
O	1321	1322	:
O	1323	1325	41
O	1325	1326	.
O	1326	1327	5
O	1327	1328	-
O	1328	1330	63
O	1330	1331	.
O	1331	1332	7
O	1332	1333	]
O	1334	1337	for
O	1338	1349	combination
O	1350	1357	therapy
O	1357	1358	,
O	1359	1362	and
B-iv-bin-percent	1363	1365	60
I-iv-bin-percent	1365	1366	%
O	1367	1368	(
O	1368	1370	95
O	1370	1371	%
O	1372	1374	CI
O	1374	1375	:
O	1376	1378	47
O	1378	1379	.
O	1379	1380	8
O	1380	1381	-
O	1381	1383	72
O	1383	1384	.
O	1384	1385	9
O	1385	1386	)
O	1387	1390	for
O	1391	1402	monotherapy
O	1402	1403	.

B-outcome	1404	1410	Median
I-outcome	1411	1414	PFS
O	1415	1418	was
B-iv-cont-median	1419	1421	10
I-iv-cont-median	1421	1422	.
I-iv-cont-median	1422	1423	8
I-iv-cont-median	1424	1430	months
O	1431	1432	(
O	1432	1434	95
O	1434	1435	%
O	1436	1438	CI
O	1438	1439	:
O	1440	1441	5
O	1441	1442	.
O	1442	1443	6
O	1443	1444	-
O	1444	1446	12
O	1446	1447	.
O	1447	1448	7
O	1448	1449	)
O	1450	1453	for
O	1454	1465	combination
O	1466	1473	therapy
O	1473	1474	,
O	1475	1478	and
B-cv-cont-median	1479	1480	6
I-cv-cont-median	1480	1481	.
I-cv-cont-median	1481	1482	5
I-cv-cont-median	1483	1489	months
O	1490	1491	(
O	1491	1493	95
O	1493	1494	%
O	1495	1497	CI
O	1497	1498	:
O	1499	1500	5
O	1500	1501	.
O	1501	1502	4
O	1502	1503	-
O	1503	1504	8
O	1504	1505	.
O	1505	1506	5
O	1506	1507	)
O	1508	1511	for
O	1512	1523	monotherapy
O	1524	1525	[
O	1525	1531	hazard
O	1532	1537	ratio
O	1538	1539	(
O	1539	1541	HR
O	1541	1542	)
O	1543	1544	0
O	1544	1545	.
O	1545	1547	69
O	1547	1548	;
O	1549	1551	95
O	1551	1552	%
O	1553	1555	CI
O	1555	1556	:
O	1557	1558	0
O	1558	1559	.
O	1559	1560	4
O	1560	1561	-
O	1561	1562	1
O	1562	1563	.
O	1563	1564	1
O	1564	1565	,
O	1566	1577	exploratory
O	1578	1579	P
O	1579	1580	-
O	1580	1585	value
O	1586	1587	=
O	1588	1589	0
O	1589	1590	.
O	1590	1592	12
O	1592	1593	]
O	1593	1594	.

O	1595	1606	Exploratory
O	1607	1615	analyses
O	1616	1624	revealed
O	1625	1628	the
B-outcome	1629	1632	PFS
I-outcome	1633	1642	advantage
I-outcome	1643	1646	for
I-outcome	1647	1658	combination
I-outcome	1659	1666	therapy
O	1667	1670	was
O	1671	1675	seen
O	1676	1678	in
O	1679	1682	the
O	1683	1691	subgroup
O	1692	1694	of
O	1695	1703	patients
O	1704	1707	who
O	1708	1716	received
O	1717	1722	prior
O	1723	1725	ET
O	1726	1729	for
O	1730	1731	>
O	1731	1732	6
O	1733	1739	months
O	1740	1741	(
O	1741	1743	HR
O	1744	1745	0
O	1745	1746	.
O	1746	1748	53
O	1748	1749	;
O	1750	1752	95
O	1752	1753	%
O	1754	1756	CI
O	1756	1757	:
O	1758	1759	0
O	1759	1760	.
O	1760	1761	3
O	1761	1762	-
O	1762	1763	0
O	1763	1764	.
O	1764	1765	9
O	1765	1766	,
O	1767	1778	exploratory
O	1779	1780	P
O	1780	1781	-
O	1781	1786	value
O	1787	1788	=
O	1789	1790	0
O	1790	1791	.
O	1791	1793	02
O	1793	1794	)
O	1794	1795	,
O	1796	1799	but
O	1800	1803	not
O	1804	1806	in
O	1807	1812	those
O	1813	1816	who
O	1817	1825	received
O	1826	1831	prior
O	1832	1834	ET
O	1835	1838	for
O	1839	1840	â‰¤
O	1840	1841	6
O	1842	1848	months
O	1848	1849	.

O	1850	1861	Palbociclib
O	1862	1865	has
O	1866	1874	clinical
O	1875	1883	activity
O	1884	1886	as
O	1887	1888	a
O	1889	1895	single
O	1896	1901	agent
O	1902	1904	in
O	1905	1910	women
O	1911	1915	with
O	1916	1926	moderately
O	1927	1937	pretreated
O	1937	1938	,
O	1939	1948	oestrogen
O	1949	1957	receptor
O	1957	1958	-
O	1958	1966	positive
O	1966	1967	,
O	1968	1972	HER2
O	1972	1973	-
O	1973	1981	negative
O	1982	1990	advanced
O	1991	1997	breast
O	1998	2004	cancer
O	2004	2005	.

O	2006	2017	Palbociclib
O	2018	2021	may
O	2022	2026	have
O	2027	2036	potential
O	2037	2039	to
O	2040	2047	reverse
O	2048	2057	endocrine
O	2058	2068	resistance
O	2069	2071	in
O	2072	2080	patients
O	2081	2085	with
O	2086	2087	a
O	2088	2095	history
O	2096	2098	of
O	2099	2107	previous
O	2108	2115	durable
O	2116	2124	response
O	2125	2127	to
O	2128	2130	ET
O	2130	2131	.

O	2132	2143	NCT02549430
O	2143	2144	.
